OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ONTEX$2.8660

Ontex Group NV

Personal ProductsVerified

Ontex Group NV exhibits a capital structure with a debt-to-equity ratio of 0.67, indicating moderate leverage. The company's liquidity position is constrained, with cash and equivalents of EUR 23.2 million and a current ratio of 0.98, suggesting limited short-term liquidity cushion. The price-to-book ratio of 0.24 and price-to-tangible-book ratio of 0.24 reflect a significant discount to book value, potentially signaling undervaluation or underlying asset impairment risks. Profitability metrics are weak, with a net loss of EUR 173.6 million and a return on equity of -18.27%. The return on assets of -8.02% further underscores operational inefficiencies. These figures fall below the industry median for return on equity and return on assets in the Personal Products sector, indicating underperformance relative to peers. Geographically, Ontex operates in Europe, North America, Brazil, Northern Africa, Australia, and Asia. However, the financial snapshot does not provide segment-specific revenue breakdowns, limiting visibility into geographic concentration risks. The company's reliance on retail trade, care institutions, and pharmacies for distribution suggests exposure to retail channel volatility and healthcare policy shifts. Growth trajectory is uncertain, with no specific revenue growth rates provided in the input data. The company's operating cash flow of EUR 123.9 million and free cash flow of EUR 12.9 million suggest some cash generation capacity, but capital expenditures of EUR 81.1 million indicate ongoing investment in operations. Analysts have assigned a mean price target of EUR 4.00, implying a potential upside of 40% from the current market price of EUR 2.86. Risk factors include liquidity constraints and a net cash position that is negative after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the net loss and weak profitability metrics raise concerns about long-term sustainability and the potential need for equity financing. Recent events include the publication of the 2023 10-K filing, which details the company's financial performance and risk factors. No recent earnings call transcripts or press releases were provided in the input data, limiting insight into management's strategic direction or near-term operational updates.

30-day price · ONTEX(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyOntex Group NV
TickerONTEX.BR
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Products
AI analysis

Business. Ontex Group NV is a Belgium-based manufacturer of disposable personal hygiene solutions for babies, women, and adults, generating revenue through retail partner brands and its own brands (canbebe, canped, and Moltex) across multiple distribution channels.

Classification. Ontex is classified under the Consumer Non-Cyclicals economic sector, Personal & Household Products & Services business sector, and Personal Products industry, with a confidence level of 0.92.

Ontex Group NV exhibits a capital structure with a debt-to-equity ratio of 0.67, indicating moderate leverage. The company's liquidity position is constrained, with cash and equivalents of EUR 23.2 million and a current ratio of 0.98, suggesting limited short-term liquidity cushion. The price-to-book ratio of 0.24 and price-to-tangible-book ratio of 0.24 reflect a significant discount to book value, potentially signaling undervaluation or underlying asset impairment risks. Profitability metrics are weak, with a net loss of EUR 173.6 million and a return on equity of -18.27%. The return on assets of -8.02% further underscores operational inefficiencies. These figures fall below the industry median for return on equity and return on assets in the Personal Products sector, indicating underperformance relative to peers. Geographically, Ontex operates in Europe, North America, Brazil, Northern Africa, Australia, and Asia. However, the financial snapshot does not provide segment-specific revenue breakdowns, limiting visibility into geographic concentration risks. The company's reliance on retail trade, care institutions, and pharmacies for distribution suggests exposure to retail channel volatility and healthcare policy shifts. Growth trajectory is uncertain, with no specific revenue growth rates provided in the input data. The company's operating cash flow of EUR 123.9 million and free cash flow of EUR 12.9 million suggest some cash generation capacity, but capital expenditures of EUR 81.1 million indicate ongoing investment in operations. Analysts have assigned a mean price target of EUR 4.00, implying a potential upside of 40% from the current market price of EUR 2.86. Risk factors include liquidity constraints and a net cash position that is negative after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the net loss and weak profitability metrics raise concerns about long-term sustainability and the potential need for equity financing. Recent events include the publication of the 2023 10-K filing, which details the company's financial performance and risk factors. No recent earnings call transcripts or press releases were provided in the input data, limiting insight into management's strategic direction or near-term operational updates.
Key takeaways
  • Ontex Group NV is trading at a significant discount to book value, with a price-to-book ratio of 0.24.
  • The company reported a net loss of EUR 173.6 million, with return on equity and return on assets both negative.
  • Liquidity is constrained, with a current ratio of 0.98 and limited cash reserves.
  • Analysts have assigned a mean price target of EUR 4.00, implying a 40% upside from the current market price.
  • The company's geographic and distribution channel diversification may provide some resilience but lacks detailed segment-level visibility.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$1.76B
Gross profit$479.4M
Operating income$79.0M
Net income-$173.6M
R&D
SG&A
D&A
SBC
Operating cash flow$123.9M
CapEx-$81.1M
Free cash flow$12.9M
Total assets$2.16B
Total liabilities$1.21B
Total equity$950.4M
Cash & equivalents$23.2M
Long-term debt$637.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$2.86
Market cap$228.8M
Enterprise value$843.3M
P/E
Reported non-GAAP P/E
EV/Revenue0.5
EV/Op income10.7
EV/OCF6.8
P/B0.2
P/Tangible book0.2
Tangible book$950.4M
Net cash-$614.5M
Current ratio1.0
Debt/Equity0.7
ROA-8.0%
ROE-18.3%
Cash conversion-71.0%
CapEx/Revenue-4.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Personal Products · cohort 225 companies
MetricONTEXActivity
Op margin4.5%16.2% medp25 16.2% · p75 16.2%bottom quartile
Net margin-9.9%10.5% medp25 10.5% · p75 10.5%bottom quartile
Gross margin27.2%60.1% medp25 60.1% · p75 60.1%bottom quartile
R&D / revenue1.8% medp25 1.8% · p75 1.8%
CapEx / revenue-4.6%-2.3% medp25 -4.4% · p75 -1.1%bottom quartile
Debt / equity67.0%12724.1% medp25 12724.1% · p75 12724.1%bottom quartile
Observations
IR observations
Mean price target4.00 EUR
Median price target4.25 EUR
High price target4.70 EUR
Low price target2.32 EUR
Mean recommendation3.33 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count3.00
Sell count1.00
Strong-sell count1.00
Mean EPS estimate0.57 EUR
Last actual EPS0.52 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 15:12 UTC#74531f76
Market quoteclose EUR 2.86 · shares 0.08B diluted
no public URL
2026-05-04 15:12 UTC#fef8ec95
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 15:13 UTCJob: 87359bdb